CD22 and non-Hodgkin lymphoma: Epratuzumab (Emab), a humanized anti-human CD22 IgG1 Ab, has previously shown promising clinical activity both as a single agent and in combination with rituximab in patients with non-Hodgkin’s lymphoma (NHL) [46].